INTRODUCTION: In the literature, HPV infection and/or p16 positivity have been consistently demonstrated to correlate with improved response rates in oropharyngeal squamous cell carcinoma (OPSCC) patients treated with primary radiotherapy (RT) alone and in combination with chemotherapy. However, the exact role of HPV/p16 positivity in patients treated with postoperative RT is still unclear. METHODS: We analyzed tumor samples for HPV-DNA and p16 expression and correlated these variables with treatment outcome in a series of 63 consecutively treated oropharyngeal cancer patients (95% stage III/IV). HPV and p16 analysis were performed using validated test systems. Survival was estimated by the Kaplan-Meier method. Cox proportional hazard regression models were applied to compare the risk of death among patients stratified according to risk factors. RESULTS: Expression of p16 or high-risk HPV-DNA was detected in 60.3% and 39.6% of the tumors, respectively. p16 expression [overall survival (OS) at 2 years: 91%] as well as HPV infection (OS at 2 years: 95%) was associated with improved OS. Mean survival in p16-positive patients was 112 months compared to 64.6 months in case of p16 negativity. All HPV-positive tumors stained positive for p16. In a multivariable analysis, p16 positivity was associated with improved OS and with disease-free survival. CONCLUSION: p16 expression and HPV infection are strongly associated with the outcome of postoperatively irradiated OPSCC patients. HPV and p16 double-negative OPSCC patients should be regarded as a distinct "very high-risk patient group" that may benefit from intensified or novel treatment combinations.
INTRODUCTION: In the literature, HPV infection and/or p16 positivity have been consistently demonstrated to correlate with improved response rates in oropharyngeal squamous cell carcinoma (OPSCC) patients treated with primary radiotherapy (RT) alone and in combination with chemotherapy. However, the exact role of HPV/p16 positivity in patients treated with postoperative RT is still unclear. METHODS: We analyzed tumor samples for HPV-DNA and p16 expression and correlated these variables with treatment outcome in a series of 63 consecutively treated oropharyngeal cancerpatients (95% stage III/IV). HPV and p16 analysis were performed using validated test systems. Survival was estimated by the Kaplan-Meier method. Cox proportional hazard regression models were applied to compare the risk of death among patients stratified according to risk factors. RESULTS: Expression of p16 or high-risk HPV-DNA was detected in 60.3% and 39.6% of the tumors, respectively. p16 expression [overall survival (OS) at 2 years: 91%] as well as HPV infection (OS at 2 years: 95%) was associated with improved OS. Mean survival in p16-positive patients was 112 months compared to 64.6 months in case of p16 negativity. All HPV-positive tumors stained positive for p16. In a multivariable analysis, p16 positivity was associated with improved OS and with disease-free survival. CONCLUSION:p16 expression and HPV infection are strongly associated with the outcome of postoperatively irradiated OPSCC patients. HPV and p16 double-negative OPSCC patients should be regarded as a distinct "very high-risk patient group" that may benefit from intensified or novel treatment combinations.
Authors: A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht Journal: Strahlenther Onkol Date: 2012-05-13 Impact factor: 3.621
Authors: Claudia Lill; Gabriela Kornek; Barbara Bachtiary; Edgar Selzer; Christian Schopper; Martina Mittlboeck; Martin Burian; Friedrich Wrba; Dietmar Thurnher Journal: Wien Klin Wochenschr Date: 2011-03-30 Impact factor: 1.704
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: D Rades; N D Seibold; A Hoffmann; M P Gebhard; F Noack; C Thorns; S E Schild Journal: Strahlenther Onkol Date: 2013-07-17 Impact factor: 3.621
Authors: H A Wolff; C R M Wolff; C F Hess; K Jung; S Sennhenn-Kirchner; M Hinterthaner; A Müller-Dornieden; W Körber; K Marten-Engelke; R Roedel; H Christiansen; C Engelke Journal: Strahlenther Onkol Date: 2013-07-12 Impact factor: 3.621
Authors: Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl Journal: Clin Oral Investig Date: 2017-03-18 Impact factor: 3.573
Authors: Thomas Kuhnt; Andreas Schreiber; Anett Pirnasch; Matthias G Hautmann; Peter Hass; Frank P Sieker; Rita Engenhart-Cabillic; Michael Richter; Kathrin Dellas; Jürgen Dunst Journal: Strahlenther Onkol Date: 2017-05-12 Impact factor: 3.621
Authors: Margret Rave-Fränk; Narges Tehrany; Julia Kitz; Martin Leu; Hanne Elisabeth Weber; Peter Burfeind; Henning Schliephake; Martin Canis; Tim Beissbarth; Holger Michael Reichardt; Hendrik Andreas Wolff Journal: Strahlenther Onkol Date: 2015-09-15 Impact factor: 3.621
Authors: Annekatrin Coordes; Klaus Lenz; Xu Qian; Minoo Lenarz; Andreas M Kaufmann; Andreas E Albers Journal: Eur Arch Otorhinolaryngol Date: 2015-07-31 Impact factor: 2.503